In February 2026, two significant policy developments took place for the rare cancer community, one in the United States and one in the United Kingdom.

While legislation does not cure cancer, it can reshape systems, remove barriers, raise awareness, and accelerate progress for patients facing rare and aggressive diseases such as osteosarcoma.

United States: The Mikaela Naylon Give Kids A Chance Act

On 3 February 2026, the President of the United States signed the Mikaela Naylon Give Kids A Chance Act into law.

The legislation reauthorises the FDA Priority Review Voucher programme, incentivising pharmaceutical companies to develop treatments for rare paediatric diseases. It also strengthens the FDA’s authority to require the study of combination cancer therapies in paediatric trials, helping to address the long standing gap between adult and childhood drug development.

Each year, nearly 16,000 children in the United States are diagnosed with cancer. Yet treatment options remain far more limited than in adult oncology. In osteosarcoma, frontline therapies have changed little in over four decades.

United Kingdom: The Rare Cancers Bill

In the UK, the Rare Cancers Bill is progressing through Parliament and is set to become law subject to Royal approval. The Bill focuses on improving data collection, transparency, and reporting for rare cancers within the national health system.

You can read the official Parliamentary details here:
https://bills.parliament.uk/bills/3779

Rare cancers, including many paediatric cancers and sarcomas, often suffer from fragmented data and limited national visibility. Strengthening reporting requirements and oversight is an important step toward ensuring these diseases are not overlooked.

Why This Matters for Osteosarcoma

Osteosarcoma remains a rare and aggressive bone cancer with limited treatment advances, particularly in relapsed or metastatic disease.

Policy reform is not the finish line. But it creates the framework for faster research, stronger accountability, and earlier access to innovation.

These developments in both the USA and the UK signal an important shift. Childhood and rare cancers are being recognised at a national policy level.

For families facing these diagnoses, that recognition is a necessary step toward meaningful progress.

Because every child deserves better options.